HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation...
solaci -
Learn More
Other

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in...
solaci -
Learn More
Other

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and...
solaci -
Learn More
Other

ESC 2020 | Atrial Fibrillation and Rhythm Control: A Matter of Time?

Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events...
solaci -
Learn More
Acute coronary syndromes

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without...
solaci -
Learn More
Antithrombotic Anticoagulants

Impact on Mortality with Rivaroxaban after Discharge

Extending thromboembolic prophylaxis with rivaroxaban in patients hospitalized for heart conditions reduce fatal and thromboembolic events by...
solaci -
Learn More
Other

When and How Could Dexamethasone Be Useful in a COVID-19 Infection?

More details have emerged on the group of COVID-19 patients who received dexamethasone in the RECOVERY trial. These...
solaci -
Learn More
Coronary disease

Rapid Drop of Antibodies in Mild COVID-19 patients

A fast drop in COVID-19 antibodies in mild patients triggers the alarm for protection against the new...
solaci -
Learn More